A recent study explores the effects of Movardol, a blend of boswellia, ginger, and N-acetylglucosamine, on symptoms of knee osteroarthritis.
Researchers in Italy have shared new study results that suggest Movardol, a supplement product combining N-acetylglucosamine, Boswellia serrata, and ginger, may help alleviate symptoms of knee osteoarthritis (OA). The registry study found that adults with OA who consumed Movardol for six months showed improvements to pain-free walking distance, stiffness, inflammatory markers, and more.
The study, published in the European Review for Medical and Pharmacological Sciences, included 54 subjects with symptomatic, moderate knee OA who were allowed to freely decide which administration they would follow for six months. The control group included 26 subjects who followed a standard management (mean age: 53.1 +/- 2), while the experimental group included 28 subjects who consumed oral Movardol supplements (mean age: 52.3 +/- 4.2). Subjects in the Movardol group consumed 3 tablets/day for the first week and 2 tablets/day for the following weeks, with each tablet containing 500 mg N-acetyl-D-glucosamine, 250 mg ginger extract with 5% gingerols, and 180 mg boswellia extract containing 65% boswellic acids.
Researchers evaluated subjects at baseline, one month after beginning supplementation, three months after beginning supplementation, and six months after supplementation for functional impairment due to knee pain by the Karnofsky Performance Scale Index. Additionally, subject knee pain, stiffness, and physical, social, and emotional functions were assessed by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and total and pain-free walking distance were measured by a treadmill test. Researchers also evaluated circulating biomarkers of inflammation and oxidative stress.
At one, three, and six months after beginning supplementation, the Movardol group showed significant improvements to the functional outcomes and pain-free walking distance. All markers assessed by the WOMAC tended to regress over the course of the entire six-month supplementation period in the Movardol group, and inflammatory markers and plasmatic content of reactive oxygen species also decreased over the same period in the experimental group.
“These preliminary results indicate the efficacy and safety of Movardol supplementation in the management of moderate knee OA,” researchers concluded. Movardol is a finished supplement product from Leonardo Medica (Empoli, Italy).
Nutritional Outlook Magazine
Bolognesi G et al., “Movardol (N-acetylglucosamine, Boswellia serrata, ginger) supplementation in the management of knee osteoarthritis: preliminary results from a 6-month registry study,” European Review for Medical and Pharmacological Sciences, vol. 20, no. 24 (December 2016): 5198–5204